Ratings by Guggenheim (Michael W. Schmidt)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/3/2025 | Exelixis | EXEL | Downgrade | Neutral (Buy) |
38.67 (41.55) |
7.45% | Details | |
| 8/7/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2025 | Blueprint Medicines | BPMC | Downgrade | Neutral (Buy) |
127.79 (129.46) |
1.31% | Details | |
| 5/15/2025 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2025 | Exelixis | EXEL | Maintain | Buy (Buy) |
|
Details | ||
| 3/12/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2025 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2024 | Deciphera | DCPH | Downgrade | Neutral (Buy) |
14.65 (25.59) |
74.68% | Details | |
| 1/2/2024 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 1/2/2024 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 11/20/2023 | Arvinas Inc. | ARVN | Upgrade | Buy (Neutral) |
20.92 (13.60) |
-34.99% | Details | |
| 1/12/2023 | Arvinas Inc. | ARVN | Downgrade | Neutral (Buy) |
30.34 (13.60) |
-55.17% | Details | |
| 1/4/2023 | Deciphera | DCPH | Upgrade | Buy (Neutral) |
16.39 (25.59) |
56.13% | Details | |
| 1/3/2023 | Xilio Therapeutics Inc | XLO | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 11/10/2022 | Xilio Therapeutics Inc | XLO | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2022 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 9/13/2022 | Rubius | RUBY | Downgrade | Neutral (Buy) |
1.07 (0.08) |
-92.52% | Details | |
| 5/12/2022 | Xilio Therapeutics Inc | XLO | Maintain | Buy (N/A) |
|
Details | ||
| 4/11/2022 | Rubius | RUBY | Maintain | Buy (N/A) |
|
Details | ||
| 11/29/2021 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 11/16/2021 | Xilio Therapeutics Inc | XLO | New Coverage | Buy (N/A) |
22.20 (0.53) |
-97.61% | Details | |
| 11/8/2021 | Deciphera | DCPH | Downgrade | Neutral (Buy) |
8.82 (25.59) |
190.14% | Details | |
| 10/28/2021 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2021 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2021 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2021 | Rubius | RUBY | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2020 | Deciphera | DCPH | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2020 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2020 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2020 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2020 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2020 | Deciphera | DCPH | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2020 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2019 | Deciphera | DCPH | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2019 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details |
